

# The Medical Letter®

## On Drugs and Therapeutics

---

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

---

**IN THIS ISSUE** (starts on next page)

**In Brief: Sibutramine (*Meridia*) Withdrawn ..... p 88**

### Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769**

---

**FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS**

The Medical Letter publications are protected by US and international copyright laws.  
Forwarding, copying or any other distribution of this material is strictly prohibited.  
For further information call: 800-211-2769

# The Medical Letter®

## On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 52 (Issue 1350)  
November 1, 2010

[www.medicalletter.org](http://www.medicalletter.org)

### IN BRIEF

#### **Sibutramine (*Meridia*) Withdrawn**

The results of a postmarketing study of its cardiovascular safety have led to the removal of the weight-loss drug sibutramine (*Meridia*) from the market in the US and Canada. It has also been withdrawn in Europe and Australia, but remains on the market in many other countries. The study that led the FDA to ask Abbott Laboratories to withdraw the drug randomized 10,744 overweight patients with cardiovascular disease, diabetes or both to sibutramine or placebo for a mean duration of 3.4 years. The primary endpoint (nonfatal myocardial infarction, nonfatal stroke, cardiovascular death or resuscitation after cardiac arrest) occurred in 561 of 4906 patients (11.4%) taking sibutramine and in 490 of 4898 (10%) taking placebo ( $p = 0.02$ ). Death from any cause occurred in 8.5% of the patients who took sibutramine and in 8.2% of those on placebo; this difference was not statistically significant.<sup>1</sup>

1. WP James et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. *N Engl J Med* 2010; 363:905.

### The Medical Letter®

On Drugs and Therapeutics

**EDITOR IN CHIEF:** Mark Abramowicz, M.D.  
**EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School  
**EDITOR:** Jean-Marie Pflomm, Pharm.D.  
**ASSISTANT EDITORS, DRUG INFORMATION:** Susan M. Daron, Pharm.D., Blaine M. Houst, Pharm.D., Corinne E. Zanoone, Pharm.D.  
**CONSULTING EDITOR:** Brinda M. Shah, Pharm.D.  
**CONTRIBUTING EDITORS:**  
Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons  
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School  
Eric J. Epstein, M.D., Albert Einstein College of Medicine  
Jules Hirsch, M.D., Rockefeller University  
David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre  
Richard B. Kim, M.D., University of Western Ontario  
Hans Meinertz, M.D., University Hospital, Copenhagen  
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine  
Dan M. Roden, M.D., Vanderbilt University School of Medicine  
F. Estelle R. Simons, M.D., University of Manitoba  
Jordan W. Smoller, M.D., Sc.D., Harvard Medical School  
Neal H. Steigbigel, M.D., New York University School of Medicine  
Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weil Medical College of Cornell University  
**SENIOR ASSOCIATE EDITORS:** Donna Goodstein, Amy Faucard  
**ASSOCIATE EDITOR:** Cynthia Macapagal Covey  
**EDITORIAL FELLOW:** Esperance A.K. Schaefer, M.D., M.P.H., Massachusetts General Hospital, Harvard Medical School  
**MANAGING EDITOR:** Susie Wong  
**ASSISTANT MANAGING EDITOR:** Liz Donohue  
**PRODUCTION COORDINATOR:** Cheryl Brown  
**EXECUTIVE DIRECTOR OF SALES:** Gene Carbona  
**FULFILLMENT & SYSTEMS MANAGER:** Cristine Romatowski  
**DIRECTOR OF MARKETING COMMUNICATIONS:** Joanne F. Valentino  
**VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy  
Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

#### Subscription Services

**Mailing Address:**  
The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537

**Subscriptions (US):**  
1 year - \$98; 2 years - \$189;  
3 years - \$279. \$49.00 per year for students, interns, residents and fellows in the US and Canada.

**Customer Service:**  
Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
Web Site: [www.medicalletter.org](http://www.medicalletter.org)  
E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

**E-mail site license inquiries to:**  
[info@medicalletter.org](mailto:info@medicalletter.org) or call 800-211-2769 x315.  
Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.

**Permissions:**  
To reproduce any portion of this issue, please e-mail your request to: [permissions@medicalletter.org](mailto:permissions@medicalletter.org)

Copyright 2010. ISSN 1523-2859